JP2020015733A5 - - Google Patents

Download PDF

Info

Publication number
JP2020015733A5
JP2020015733A5 JP2019149672A JP2019149672A JP2020015733A5 JP 2020015733 A5 JP2020015733 A5 JP 2020015733A5 JP 2019149672 A JP2019149672 A JP 2019149672A JP 2019149672 A JP2019149672 A JP 2019149672A JP 2020015733 A5 JP2020015733 A5 JP 2020015733A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
polypeptide
subject
fgfr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019149672A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020015733A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2019149672A priority Critical patent/JP2020015733A/ja
Priority claimed from JP2019149672A external-priority patent/JP2020015733A/ja
Publication of JP2020015733A publication Critical patent/JP2020015733A/ja
Publication of JP2020015733A5 publication Critical patent/JP2020015733A5/ja
Pending legal-status Critical Current

Links

JP2019149672A 2019-08-19 2019-08-19 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体3(fgr3)ポリペプチド Pending JP2020015733A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019149672A JP2020015733A (ja) 2019-08-19 2019-08-19 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体3(fgr3)ポリペプチド

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2019149672A JP2020015733A (ja) 2019-08-19 2019-08-19 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体3(fgr3)ポリペプチド

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015553175A Division JP2016506914A (ja) 2013-01-16 2013-01-16 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体3(fgr3)ポリペプチド

Publications (2)

Publication Number Publication Date
JP2020015733A JP2020015733A (ja) 2020-01-30
JP2020015733A5 true JP2020015733A5 (cg-RX-API-DMAC7.html) 2020-09-10

Family

ID=69580027

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019149672A Pending JP2020015733A (ja) 2019-08-19 2019-08-19 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体3(fgr3)ポリペプチド

Country Status (1)

Country Link
JP (1) JP2020015733A (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110272900B (zh) * 2019-04-19 2024-03-26 中国人民解放军陆军军医大学 用于制备骨骼发育异常猪模型的sgRNA及其应用
KR20250162619A (ko) * 2023-03-20 2025-11-18 아센디스 파마 그로우쓰 디스오더스 에이/에스 연골무형성증을 가진 인간 대상에서의 흉요추 변형의 치료 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996041523A1 (en) * 1995-06-12 1996-12-27 Yeda Research And Development Co., Ltd. Fgf9 as a specific ligand for fgfr3
IL159177A0 (en) * 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
BRPI0203172B8 (pt) * 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
JP2003104908A (ja) * 2001-09-28 2003-04-09 Ichikazu Nakao 軟骨無形成症治療剤
IL156495A0 (en) * 2003-06-17 2004-01-04 Prochon Biotech Ltd Use of fgfr3 antagonists for treating t cell mediated diseases
AU2005216547B2 (en) * 2004-02-24 2009-03-12 Allergan, Inc. Botulinum toxin screening assays
NZ565511A (en) * 2005-07-22 2011-03-31 Five Prime Therapeutics Inc Compositions and methods of treating disease with FGFR fusion proteins
WO2008133873A2 (en) * 2007-04-25 2008-11-06 Aveo Pharmaceuticals, Inc. Fgf-binding fusion proteins
JP6055779B2 (ja) * 2010-12-27 2016-12-27 アレクシオン ファーマシューティカルズ, インコーポレイテッド ナトリウム利尿ペプチドを含む組成物およびその使用方法

Similar Documents

Publication Publication Date Title
DE69433820T2 (de) Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
US10786555B2 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
US20230241168A1 (en) April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof
US9453067B2 (en) Stable pharmaceutical liquid formulations of the fusion protein TNFR:Fc
JP2023099045A (ja) インターロイキン-2/インターロイキン-2受容体アルファ融合タンパク質および使用方法
US20240226236A9 (en) Nerve growth factor fusion protein, preparation method and use thereof
CA2634547C (en) Stable ctla4 formulation for subcutaneous administration
DK2633865T3 (en) USE OF INTERLEUKIN-22 IN THE TREATMENT OF VIRAL HEPATITIS
JP2010518079A5 (cg-RX-API-DMAC7.html)
JP2016537340A5 (cg-RX-API-DMAC7.html)
JP2022512541A (ja) Pd-1系キメラタンパク質を含む併用療法
JP2019151655A (ja) 関節リウマチの治療のための可溶性cd24の使用方法
CA3128113A1 (en) Pharmaceutical taci-fc fusion protein formulation
JP2016506914A5 (cg-RX-API-DMAC7.html)
JP2016506912A5 (cg-RX-API-DMAC7.html)
AU2024204870A1 (en) Stable formulations of fibronectin based scaffold domain proteins that bind to myostatin
JP6480154B2 (ja) エタネルセプトの凍結乾燥製剤
AU2019364063B2 (en) Pharmaceutical composition for treating aplastic anemia
US7619066B2 (en) IL-1ra variants
KR20250048156A (ko) 제제에 접합된 인슐린 유사 성장 인자 1 수용체 리간드를 사용한 자가면역 질환의 치료
JP7606173B2 (ja) I型インターフェロンの中和型Fc融合タンパク質及びその使用
US7323444B2 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
Weaver Efficacy and safety of the anti-TNF biologic agents
RU2023110696A (ru) СПОСОБ ЛЕЧЕНИЯ IgA-НЕФРОПАТИИ С ИСПОЛЬЗОВАНИЕМ СЛИТОГО БЕЛКА TACI-FC
HK40059370A (en) Pharmaceutical composition for treating aplastic anemia